ArticleBiochemistry and cell biology = Biochimie et biologie cellulaire2017
Oral recombinant human or mouse lactoferrin reduces Mycobacterium tuberculosis TDM induced granulomatous lung pathology.
Article in Biochemistry and cell biology = Biochimie et biologie cellulaire, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Modulation of TDM-induced granuloma pathology by human lactoferrin: a persistent effect in mice.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Article
- Modulation of TDM-induced granuloma pathology by human lactoferrin: a persistent effect in mice.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023Article
- Time to Kill and Time to Heal: The Multifaceted Role of Lactoferrin and Lactoferricin in Host Defense.Pharmaceutics · 2023Review
- Can Lactoferrin, a Natural Mammalian Milk Protein, Assist in the Battle against COVID-19?Nutrients · 2022Review
- Recombinant Human Lactoferrin Reduces Inflammation and Increases Fluoroquinolone Penetration to Primary Granulomas During Mycobacterial Infection of C57Bl/6 Mice.Archivum immunologiae et therapiae experimentalis · 2022Article
- Antibacterial properties of lactoferrin: A bibliometric analysis from 2000 to early 2022.Frontiers in microbiology · 2022Review
- Antibacterial and Anti-biofilm Activity of the Human Breast Milk Glycoprotein Lactoferrin against Group B Streptococcus.Chembiochem : a European journal of chemical biology · 2021Article
- The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm.International immunopharmacology · 2021Review
- Mycobacterial trehalose 6,6'-dimycolate induced vascular occlusion is accompanied by subendothelial inflammation.Tuberculosis (Edinburgh, Scotland) · 2019Article
- Lactoferrin in a Context of Inflammation-Induced Pathology.Frontiers in immunology · 2017Review
- Host Antimicrobial Peptides: The Promise of New Treatment Strategies against Tuberculosis.Frontiers in immunology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Trehalose 6'6-dimycolate (TDM) is the most abundant glycolipid on the cell wall of Mycobacterium tuberculosis (MTB). TDM is capable of inducing granulomatous pathology in mouse models that resembles those induced by MTB infection. Using the acute TDM model, this work investigates the effect of recombinant human and mouse lactoferrin to reduce granulomatous pathology. C57BL/6 mice were injected intravenously with TDM at a dose of 25 μg·mouse
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.